Collaborate With Us

Oral GLP-1

Primary Indications

Treatment of Type 2 diabetes mellitus and obesity

Stage of Development
Recruiting 3 Month Phase IIa
  • Outlicensing opportunity - providing oral formulation technology to GLP-1 analogue
  • Stimulates insulin formation and release when blood glucose levels are high
  • Reduces glucose output from the liver
  • Improves insulin sensitivity and the function of ß-cells
  • Slows emptying of stomach and reduces desire to eat
STAY UP TO DATE

Get our latest insights and project announcements

Subscribe now

DIABETOLOGY

Oral Capsule Technology for Insulin, GLP-1 and Other Protein-Based Therapies and Combinations.

HEADQUARTERS:
23/27 Seaton place,
Charter Place, St Helier,
Jersey JE1 1JY,
Channel Islands

The London BioScience Innovation Centre
2 Royal College Street, London, NW1 0NH
United Kingdom

Quick Links

Stay in Touch

Copyright © 2026 Diabetology Ltd. All rights reserved.

Get in Touch